GEMTESA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GEMTESA (GEMTESA).
Selective antagonist of beta-3 adrenergic receptor in the detrusor muscle, causing relaxation and increasing bladder capacity.
| Metabolism | Primarily metabolized by CYP2D6 and to a lesser extent CYP3A4; also undergoes O-glucuronidation by UGT2B10, UGT2B15, and UGT2B17. |
| Excretion | Approximately 78% of the dose is excreted via feces (49% as unchanged drug, 29% as metabolites) and 21% via urine (13% as unchanged drug, 8% as metabolites). |
| Half-life | The terminal elimination half-life is approximately 8.4 hours in healthy subjects, supporting once-daily dosing in clinical practice. |
| Protein binding | Approximately 71% bound to serum proteins, primarily to albumin. |
| Volume of Distribution | The volume of distribution is approximately 136 L (or about 1.7 L/kg assuming 80 kg), indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is approximately 76% under fasting conditions; administration with a high-fat meal reduces Cmax and AUC by 30-35%. |
| Onset of Action | Evidence of clinical effect is observed within 2 weeks of once-daily oral administration at 75 mg. |
| Duration of Action | The duration of action supports once-daily dosing; clinical effect is maintained over 24 hours with regular administration. |
75 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR 15-89 mL/min. Not recommended for GFR <15 mL/min or ESRD. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Not recommended. Child-Pugh C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in patients <18 years. |
| Geriatric use | No specific dose adjustment; caution due to potential increased anticholinergic effects in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GEMTESA (GEMTESA).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Consider developmental and health benefits of breastfeeding along with maternal need. |
| Teratogenic Risk | No human data; animal studies show no teratogenicity at exposures up to 14 times MRHD. Risk cannot be ruled out; use only if benefit justifies risk. |
| Fetal Monitoring | No specific monitoring required. Standard prenatal care. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to vibegron or any ingredients","Urinary retention","Gastric retention","Uncontrolled narrow-angle glaucoma"]
| Precautions | ["Urinary retention","Impaired gastric motility","Severe hepatic impairment","Hypertension and cardiovascular events (including QT prolongation)"] |
Loading safety data…
| Fertility Effects | No human data; animal studies showed no impairment of fertility at exposures up to 27 times MRHD. |